Dasatinib + Quercetin (D+Q) For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox"> [@xu2018]
| Category | Value | [@bussian2018]
|---------|-------| [@musi2018]
| Combination | Dasatinib + Quercetin | [@zhang2023]
| Abbreviation | D+Q | [@ogrodnik2019]
| Class | Senolytic agents | [@chaib2022]
| Mechanism | Bcl-2 family inhibition | [@kirkland2023]
| Status | Phase I/II clinical trials | [@justice2024]
| Administration | Oral, intermittent | [@hickson2023]
</div>
Dasatinib + Quercetin (D+Q) For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox"> [@xu2018]
| Category | Value | [@bussian2018]
|---------|-------| [@musi2018]
| Combination | Dasatinib + Quercetin | [@zhang2023]
| Abbreviation | D+Q | [@ogrodnik2019]
| Class | Senolytic agents | [@chaib2022]
| Mechanism | Bcl-2 family inhibition | [@kirkland2023]
| Status | Phase I/II clinical trials | [@justice2024]
| Administration | Oral, intermittent | [@hickson2023]
</div>
Dasatinib + Quercetin (D+Q) is the most extensively studied senolytic drug combination, consisting of the tyrosine kinase inhibitor dasatinib and the flavonoid quercetin["@kirkland2018"]. This combination selectively eliminates senescent cells that accumulate with age and contribute to chronic inflammation and tissue dysfunction, making it a promising therapeutic approach for neurodegenerative diseases.
The rationale for combining these two drugs comes from their complementary mechanisms: dasatinib targets Bcl-2 family anti-apoptotic proteins while quercetin inhibits multiple pro-survival pathways, together effectively inducing [apoptosis](/entities/apoptosis) in senescent cells while sparing normal cells.
| Property | Dasatinib | Quercetin |
|----------|-----------|-----------|
| Class | Tyrosine kinase inhibitor | Flavonoid |
| Primary target | Bcr-Abl, Src kinases | PI3K, Bcl-2, [mTOR](/mechanisms/mtor-signaling-pathway) |
| FDA approval | Yes (leukemia) | No (dietary supplement) |
| Brain penetration | Moderate | Moderate |
| Half-life | 3-5 hours | 11-16 hours |
The D+Q combination works synergistically:
| Trial | Phase | Condition | Status | Key Finding |
|-------|-------|-----------|--------|-------------|
| NCT02848131 | I | COPD | Completed | Safety established |
| NCT03415087 | I | Alzheimer's | Completed | Safety, biomarker signals |
| NCT03675724 | I | IPF | Completed | Reduced senescent cells |
| Trial | Phase | Condition | Status |
|-------|-------|-----------|--------|
| NCT04685590 | I/II | Parkinson's | Recruiting |
| NCT04833517 | II | Cognitive decline | Planning |
From completed trials:
| Model | Outcome | Mechanism |
|-------|---------|-----------|
| 3xTg-AD mice | Reduced cognitive decline | Clearance of senescent [microglia](/cell-types/microglia-neuroinflammation) |
| Tauopathy model | Less [tau](/proteins/tau) pathology | Senolytic effect |
| Aged mice | Improved cognition | Reduced neuroinflammation |
| Model | Outcome | Mechanism |
|-------|---------|-----------|
| MPTP model | Protected DA [neurons](/entities/neurons) | Senescent glial clearance |
| [α-synuclein](/proteins/alpha-synuclein) mice | Reduced aggregation | [Autophagy](/entities/autophagy) enhancement |
| Aged mice | Improved motor function | Multi-target effects |
The original senolytic protocol uses intermittent dosing:
| Parameter | Value |
|-----------|-------|
| Dasatinib dose | 100 mg |
| Quercetin dose | 1000 mg |
| Frequency | 3 days/week or 2 consecutive days/week |
| Cycle length | Continuous |
| Protocol | Dasatinib | Quercetin | Schedule |
|----------|-----------|-----------|----------|
| Original | 100mg | 1000mg | 3 days/week |
| Low-dose | 50mg | 500mg | Daily |
| Pulsed | 100mg | 1000mg | 2 days/week |
| Event | Frequency | Severity |
|-------|-----------|----------|
| Nausea | 20-30% | Mild-moderate |
| Fatigue | 15-20% | Mild |
| Fluid retention | 10-15% | Manageable |
| Headache | 10% | Mild |
The study of Dasatinib + Quercetin (D+Q) For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Key biomarkers for D+Q response:
| Agent | Advantage | Stage |
|-------|-----------|-------|
| Fisetin | Natural, well-tolerated | Phase II |
| Navitoclax | Potent Bcl-2 inhibitor | Phase I |
| AMPK activators | Multiple benefits | Preclinical |
The D+Q combination represents the most clinically advanced senolytic therapy. While challenges remain regarding brain penetration and optimal dosing, the strong preclinical data and growing clinical evidence support continued development for neurodegenerative diseases. The ongoing Phase I/II trials in Parkinson's disease will provide crucial efficacy data.
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
Related Analyses: